XNAS
KPRX
Market cap2mUSD
Jun 16, Last price
3.01USD
1D
-0.33%
1Q
-6.52%
Jan 2017
-99.97%
IPO
-99.99%
Name
Kiora Pharmaceuticals Inc
Chart & Performance
P/E
0.63
P/S
0.14
EPS
4.77
Div Yield, %
—
Shrs. gr., 5y
120.29%
Rev. gr., 5y
42.93%
Revenues
16m
Net income
4m
P
CFO
9m
P
Earnings
Aug 07, 2025
Profile
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 16,020 | |||||||||
Cost of revenue | 13,385 | 12,717 | 11,861 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 2,635 | (12,717) | (11,861) | |||||||
NOPBT Margin | 16.45% | |||||||||
Operating Taxes | 2,065 | 90 | (113) | |||||||
Tax Rate | 78.35% | |||||||||
NOPAT | 570 | (12,808) | (11,748) | |||||||
Net income | 3,595 -128.73% | (12,514) -7.88% | (13,584) -17.15% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 14,999 | 6,154 | 8,621 | |||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 23 | 94 | 106 | |||||||
Long-term debt | 91 | 167 | 212 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 4,191 | 5,129 | 3,203 | |||||||
Net debt | (26,678) | (2,194) | (5,696) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | 8,559 | (9,557) | (10,428) | |||||||
CAPEX | (6) | 1 | ||||||||
Cash from investing activities | (22,663) | 6 | ||||||||
Cash from financing activities | 15,498 | 5,966 | 8,621 | |||||||
FCF | 1,367 | (13,494) | (11,637) | |||||||
| Balance | ||||||||||
Cash | 26,792 | 2,455 | 5,965 | |||||||
Long term investments | 49 | |||||||||
Excess cash | 25,991 | 2,455 | 6,014 | |||||||
Stockholders' equity | (143,397) | (147,083) | (134,628) | |||||||
Invested Capital | 173,405 | 158,475 | 149,450 | |||||||
ROIC | 0.34% | |||||||||
ROCE | 8.64% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 4,125 | 538 | 732 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 2,655 | (12,655) | (11,819) | |||||||
EV/EBITDA | ||||||||||
Interest | 21 | 11 | 9 | |||||||
Interest/NOPBT | 0.81% | |||||||||